



VentriPoint Diagnostics Installs Cardiac Image Analysis System at the Rikshospitalet in Oslo, Norway

This is second installation of ten planned installations in the next 6 months

Monday, November 29, 2010

SEATTLE, WASHINGTON--(Marketwire - Nov. 29, 2010) - VentriPoint Diagnostics ("VentriPoint") (TSX VENTURE:VPT), a company focused on providing effective 3D technology to monitor right heart function in children and adults, today announced the second successful deployment of its VentriPoint Medical System ("VMS") at the Rikshospitalet University Hospital in Oslo, Norway.

"This deployment of our tool in Europe is a milestone for VentriPoint and we are delighted that Dr. Henrik Brun and his colleagues will be using the system on Tetralogy of Fallot (a heart disease usually referred to as 'blue-baby') patients as well as expanding the use to patients who have had a valve implanted in their pulmonary artery," said Dr. George Adams, VentriPoint's CEO.

"We are enthusiastic to begin to use the VentriPoint system with patients in our hospital. The ease of use of the system and its potential to replace MRI studies will hopefully make a difference in the care of children with congenital heart disease," said Dr. Henrik Brun, cardiologist at Rikshospitalet.

The Rikshospitalet University Hospital is a national reference hospital responsible for introducing and developing new medical examination methods, treatment methods and follow-ups. It conducts more than 50 per cent of the total medical research in Norwegian medical centres.

What is significant about this deployment is that it is the second installation of the diagnostic tool of the ten slated for advancing the merit and value of the VentriPoint system in diagnosing heart disease in children and adults. The company is manufacturing ten systems and has selected seven leading pediatric cardiologists at world-renown hospitals to be the first users. The last three systems will be going to adult cardiologists with large patient groups with pulmonary hypertension. A number of European, Canadian and US hospitals have submitted a request to be one of the first adult users. The company will decide by the end of the year the last three sites for this deployment. Additional systems will become available next year as the company obtains reimbursement codes and expands the applications to a broader array of congenital heart diseases and pulmonary hypertension.

There are 191 specialized pediatric hospitals in Europe, which would benefit from VMS systems, which diagnoses and monitors children with congenital heart disease (CHD). In addition, there are many hospitals, which monitor adults with CHD. The company estimates the European market for its system for CHD would be \$20M per year and more than \$100M for other heart disorders.

In other news, VentriPoint will today file its quarterly financial statements and MD&A and they can be viewed on www.sedar.com .

About VentriPoint Diagnostics Ltd:

VentriPoint creates diagnostic systems to monitor patients with heart disease, the number one cause of death in developed countries. The VMS is the first cost-effective and accurate diagnostic tool for measuring right ventricle heart function. Congenital heart disease is the first application with additional applications in process to enable monitoring of all major heart diseases including pulmonary hypertension, cardiovascular disease and heart failure - a \$10 Billion market potential. Canada and Europe (CE Mark) have granted approval for the sale of its VMS diagnostic tool and a 510(k) submission is currently being reviewed by the U.S. Federal Drug Administration. For further information about VentriPoint go to www.ventripoint.com .

Cautionary Note Regarding Forward-Looking Statements - Certain statements contained herein constitute forward-looking statements, including statements concerning the anticipated closing date of the Offering and the anticipated use of proceeds. We believe the expectations reflected in those forward-looking statements are reasonable but no assurance can be given that these expectations will prove to be correct and such forward-looking statements included herein should not be unduly relied upon. Closing could be delayed if VentriPoint cannot obtain necessary regulatory approvals within anticipated timelines and will not be completed unless certain conditions customary for transactions of this kind are satisfied. The forward-looking statements included in this press release are made as of the date of this press release and VentriPoint disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities legislation.

This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Neither the TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

For further information contact:

Ventripoint Diagnostics .
George Adams
President & CEO
Ph: (403) 283-0221
Fax: (403) 283-2309
info@ventripoint.com
www.ventripoint.com

The Howard Group Inc.
Peter Weichler/Dave Burwell
Investor Relations
Toll Free: 1-888-221-0915
Phone: (403) 221-0915
Info@howardgroupinc.com
www.howardgroupinc.com